|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
CTD_human |
Elp3 links tRNA modification to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer.
|
27811057 |
2016 |
|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
CTD_human |
Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.
|
25330770 |
2014 |
|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
CTD_human |
MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro.
|
24014025 |
2013 |
|
Mammary Neoplasms
|
0.380 |
PosttranslationalModification
|
group |
BEFREE |
We therefore quantified Vimentin DNA methylation using MALDI-TOF mass spectrometry in breast tumors and matched normal pairs in association with gene expression and survival in a hospital-based study of breast cancer patients.
|
23239149 |
2013 |
|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
BEFREE |
Here, we show that human breast tumor biomarker miR-30c regulates invasion by targeting the cytoskeleton network genes encoding twinfilin 1 (TWF1) and vimentin (VIM).
|
23224145 |
2013 |
|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
BEFREE |
Treatments of human non-tumorigenic mammary epithelial and breast tumor cells with Lidocaine or Tetracaine caused rapid collapse of vimentin filaments.
|
21069453 |
2011 |
|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
CTD_human |
Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization.
|
21501481 |
2011 |
|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
BEFREE |
Since vimentin and laminin staining is widely used by pathologists for diagnostic purposes, thus demonstrating the robustness of their specific antibodies, the immunohistochemical evaluation of these two molecules could be used in identification of basal-like breast tumours in both sporadic/familial cases.
|
17105822 |
2007 |
|
Mammary Neoplasms
|
0.380 |
AlteredExpression
|
group |
LHGDN |
Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion.
|
17585878 |
2007 |
|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
BEFREE |
Our results therefore implicate SIP1 in the regulation of vimentin observed in the EMT associated with breast tumor cell migration, a pathway that may contribute to the metastatic progression of breast cancer.
|
16568083 |
2006 |
|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
LHGDN |
Our results therefore implicate SIP1 in the regulation of vimentin observed in the EMT associated with breast tumor cell migration, a pathway that may contribute to the metastatic progression of breast cancer.
|
16568083 |
2006 |
|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
BEFREE |
This is mainly supported by the significantly higher incidence of vimentin-expressing breast cancers compared to any other myoepithelial breast tumours and the fact that vimentin is already observed in ductal in situ components.
|
15906273 |
2005 |
|
Mammary Neoplasms
|
0.380 |
Biomarker
|
group |
LHGDN |
Transactivation of vimentin by beta-catenin in human breast cancer cells.
|
12750294 |
2003 |